FDA approves AstraZeneca Qternmet XR release tablets to improve blood sugar levels in adult patients with type 2 diabetes

recently, AstraZeneca announced thethe FDA's(http://approved the release of the Qternmet XR reprieve developed by thecompany(http://to improve blood sugar levels in adult patients with type 2 diabetes in combination with diet and exerciseQternmet XR is an oral triabinther therapy consisting of dapagliflozin, saxagliptin, and metforminQternmet XR is a daily compound pill consisting of three approveddrug(http://Among them, Daglenet is a specific sodium glucose co-transport protein 2 (SGLT-2) inhibitor, which inhibits the reabsorption of glucose by the kidneys, and expels more glucose from the urinechagledin is a dipeptide-based peptide-4 (DPP-4) inhibitor that suppresses the secretion of glucagon by stimulating the secretion of incretin, thus reducing blood sugar levelsMetformin has long been the drug of choice for the treatment of type 2 diabetesThis approval is based on the results of two Phase 3 clinicaltrial(http:// , which assessed the efficacy of adding a combination of dagelin and sagretin to the background therapy of metformin In both clinical trials, a combination of 5 mg dagelinet/5 mg salegin or 10 mg dageletin net/5 mg salegin was able to count and significantly reduce the level of hbA1c in patients and increase the number of patients who met the target level of HbA1c treatment